Preferred Label : metachromatic leukodystrophy, nos;

Détails


Consulter ci-dessous une sélection des principales ressources :

Vous pouvez consulter :


https://has-sante.fr/jcms/p_3294780/fr/avis-n-2021-0074/dc/sem-du-21-octobre-2021-du-college-de-la-haute-autorite-de-sante-relatif-au-projet-d-arrete-limitant-l-utilisation-de-medicaments-de-therapie-genique-indiques-dans-le-traitement-des-enfants-atteints-de-leucodystrophie-metachromatique-a-certains-etablissements-de-sante
2021
France
public health guidelines
metachromatic leukodystrophy, nos
drug utilization
Child
withholding treatment
indicators
schools
Child
child, nos
drug therapy
genetic therapy
medical futility
suggestive of
leukodystrophy, metachromatic
attitude to health
Metachromatic leukodystrophy
indicators and reagents
Child
disease
indication of
Gene therapy
Child
health facilities
child
therapy, nos
judgment
gene therapy
drug, nos

---
http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=FR&Expert=309263
2014
scientific and technical information
leukodystrophy, metachromatic, juvenile
metachromatic leukodystrophy, nos
leukodystrophy, metachromatic

---
http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=FR&Expert=309271
2014
scientific and technical information
leukodystrophy, metachromatic
metachromatic leukodystrophy, nos
adulthood
leukodystrophy, metachromatic, adult

---
http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=FR&Expert=309256
2014
scientific and technical information
metachromatic leukodystrophy, nos
metachromatic leukodystrophy, infant
leukodystrophy, metachromatic

---
Nous contacter.
31/07/2025


[Accueil] [Haut de page]

© CHU de Rouen. Toute utilisation partielle ou totale de ce document doit mentionner la source.